Inventor

FREEMAN GORDON J

66 patents

⚠️ This page may combine multiple inventors who share the name “FREEMAN GORDON J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

FREEMAN GORDON J

DANA FARBER CANCER INST INC

Human anti-PD-1 antibodies and uses therefor

Methods of upmodulating an immune response with non-activating forms of B7-4

B7-2: a CTLA4/CD28 ligand

Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor

Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1

Tumor cells with increased immunogenicity and uses therefor

Fusion proteins of novel CTLA4/CD28 ligands and uses therefore

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use

Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof

Methods for inhibiting the interaction of B7-2 with its natural ligand

CTLA4/CD28 ligands and uses therefor

Nucleic acid molecules encoding B7-1

Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand

Methods for screening for compounds that modulate PD-1 signaling

Methods of inducing a T cell mediated immune response by administering antigen presenting B cells

Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin

Nucleic acids encoding CD100 molecules

Polypeptides comprising a B7 extracellular domain

CD100 antigen and uses therefor

DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use

Anti-PD-L1 monoclonal antibodies and fragments thereof

Agents that modulate immune cell activation and methods of use thereof

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents

Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents

BRIGHAM & WOMENS HOSPITAL

Compositions and methods related to TIM-3, a Th1-specific cell surface molecule

Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cells

B7-specific antibodies

T cell costimulatory polypeptides containing alternative domains

GENETICS INST LLC

PD-1, a receptor for B7-4, and uses therefor

Nucleic acids encoding B7-2 fusion proteins

GENETICS INST

Downmodulating an immune response with multivalent antibodies to PD-1

Therapeutic compositions for inhibiting the interactions of B7-1 and B7-2 with their natural ligands

FREEMAN GORDON J

Anti-PD-L1 antibodies and uses therefor

Fastener means for a leg brace to connect to a shoe

KUCHROO VIJAY K

Compositions and methods related to TIM-3, a TH1-specific cell surface molecule

Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cells

HARVARD COLLEGE

Tumor cells with increased immunogenicity and uses therefor

Tumor cells with increased immunogenicity and uses therefor

US NAVY

Methods for selectively stimulating proliferation of T cells

WYETH CORP

Methods for screening for compounds that modulate pd-1 signaling

REPLIGEN CORP

Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies

DANA FARBER CANCER INST BRIGHA

Nucleic acids encoding B7-1 and B7-2 molecules

BRIGHAM & WOMAN S HOSPITAL

B7-1 and B7-2 polypeptides

JONES JENNIFER

Modulation of TIM receptor activity in combination with cytoreductive therapy

UNIV LELAND STANFORD JUNIOR

T cell regulatory genes and methods of use thereof

GENTICS INST INC

Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor